银屑病生物制剂持续性的预测因素:系统综述与荟萃分析
荟萃分析显示肥胖和女性性别预测停药,合并银屑病关节炎预测持续用药,女性性别还预测因副作用停药。
要点
- 肥胖(HR 1.21)与女性(HR 1.22)预测生物制剂停药。
- 合并银屑病关节炎预测生物制剂持续用药(HR 0.83)。
- 女性性别预测因副作用停药(合并HR 2.16)。
核心结论
- 荟萃分析表明女性性别和肥胖预测生物制剂停药,合并银屑病关节炎预测生物制剂持续用药。
- 女性性别预测因副作用导致的生物制剂停药,合并HR为2.16(95%CI 1.39-3.35,I2=67%)。
研究设计与样本
- 系统综述与荟萃分析,通过预设检索标准系统检索银屑病生物制剂持续性研究。
主要发现
- 肥胖预测治疗停药,HR为1.21(95%CI 1.10-1.32,I2=0%)。
- 女性性别预测治疗停药,HR为1.22(95%CI 1.07-1.38,I2=84%)。
- 合并银屑病关节炎预测生物制剂持续用药,HR为0.83(95%CI 0.80-0.86,I2=0%)。
- 吸烟、代谢综合征、生物制剂初治、年龄、DLQI、血脂异常、高社会经济地位和合并甲氨蝶呤等因素因报告不足未纳入荟萃分析。
关键数值与推荐
- HR>1表示生物制剂停药,HR<1表示生物制剂持续用药。
- 仅对至少两项研究中出现的预测因素进行荟萃分析。
临床怎么用
- 临床优化银屑病生物制剂治疗时,可关注女性性别与肥胖等停药预测因素。
- 合并银屑病关节炎可能提示生物制剂持续性更好。
局限性
- 吸烟、代谢综合征、生物制剂初治、年龄、DLQI、血脂异常、高社会经济地位和合并甲氨蝶呤等因素报告不足,未能进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term therapy for psoriasis is impaired by gradual loss of effectiveness and treatment discontinuation. Identifying factors that affect biologic drug survival may help in treatment optimization. OBJECTIVES: To identify factors that predicted biologic drug persistence or discontinuation in a real-life setting. METHODS: We identified studies of biologic persistence in psoriasis through a comprehensive, systematic literature search using predefined search criteria. Studies were screened by title and abstract then further by full-text review. Hazard ratio (HR) data were extracted for all available predictive factors (HRs > 1 denoted biologic discontinuation, and HRs < 1 denoted biologic persistence). A meta-analysis of HRs (random-effects model) was used to assess any predictive factor included in at least two studies. RESULTS: Sixteen cohort studies were included in the review, with a total of 32 194 patients. A meta-analysis was performed on 13 studies (n = 29 802): nine for female sex (n = 28 090), six for obesity (n = 9311) and six for psoriatic arthritis (n = 24 444). Obesity and female sex predicted treatment discontinuation, with HRs of 1.21 [95% confidence interval (CI) 1.10-1.32, I2 = 0%] and 1.22 (95% CI 1.07-1.38, I2 = 84%), respectively. Concomitant psoriatic arthritis predicted biologic persistence (HR 0.83, 95% CI 0.80-0.86, I2 = 0%). Female sex predicted biologic discontinuation due to side-effects, with a pooled HR of 2.16 (95% CI 1.39-3.35, I2 = 67%). Other reported predictive factors (smoking, metabolic syndrome, biologic naivety, age, Dermatology Life Quality Index, dyslipidaemia, high socioeconomic status and concomitant methotrexate) were insufficiently reported for meta-analysis. CONCLUSIONS: Our meta-analysis demonstrates that female sex and obesity predict biologic discontinuation, and concomitant psoriatic arthritis predicts biologic survival. What's already known about this topic? Ineffectiveness is the main factor that causes drug discontinuation during long-term treatment of psoriasis. It is unclear which factors and comorbidities impact drug persistence. What does this study add? Female sex and obesity predict biologic discontinuation due to ineffectiveness and adverse events. Concomitant psoriatic arthritis is associated with improved drug persistence.
引用
- Mourad A, Straube S, Armijo-Olivo S, et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019. PMID: 30729500. doi:10.1111/bjd.17738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。